logo-loader

XPhyto Therapeutics updates on its thin film cannabis delivery and dosage systems

Published: 11:50 12 Nov 2019 EST

Xphyto Therapeutics Corp. - XPhyto Therapeutics Corp provides update on its thin film cannabis delivery and dosage systems being development by German subsidiary Vektor Pharma TF GmbH
The opportunity to produce a well-defined dosage form has emerged as a major opportunity for XPhyto

XPhyto Therapeutics Corp (CSE:XPHY) (OTCMKTS:XPHYF) on Tuesday provided an update on its thin film cannabis delivery and dosage systems.

The delivery and dosage systems are being development by XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH, which is a narcotics manufacturer, importer, and researcher located near Munich.

For over a decade, Vektor's founder and managing director Thomas Beckert has been a leader in the development, testing and manufacture of thin film narcotics delivery systems, primarily transdermal patches and sublingual (oral) strips for the clinical management of pain. 

READ: XPhyto Therapeutics forges partnership with leading cannabis grower

In addition to Vektor's expertise working with conventional pain narcotics such as fentanyl, hydromorphone, and oxycodone, recent work has focused on the development of efficient cannabis delivery and dosage systems.

As the cannabis industry evolves, the opportunity to produce a well-defined dosage form has emerged as a major opportunity for XPhyto. Results from initial studies using Vektor's formulation and oral delivery system for CBD have been extremely encouraging, demonstrating significant potential timing and efficiency advantages over other common oral methods, the company said.

Strong scientific data supporting XPhyto's non-inhalable cannabis delivery systems is significant in light of recent reports concerning e-cigarette and vape-related illnesses in North America. 

In the past 30 days, both the US Food & Drug Administration and the US Centers for Disease Control & Prevention have issued public statements warning consumers about lethal potential side effects that may be associated with e-cigarettes and vaping products. 

XPhyto said it and Vektor are prioritizing non-inhalable cannabis development programs for clinical advancement.

In addition to the global medical market, XPhyto also said it is exploring near-term commercial opportunities for thin film consumer products in legal jurisdictions, including Canada.

Shares of XPhyto gained 1.1% in Canada at C$0.89 by midday Tuesday.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

29 minutes ago